Biogen (BIIB) Gets a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Piper Sandler Remains a Buy on Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Hosted on MSN11mon
Teva upgraded to Overweight at Piper Sandler on multiple expansion
Teva Pharmaceutical (NYSE:TEVA) traded higher in the morning hours Monday after Piper Sandler upgraded ... margin recovery/ expansion. Analyst David Amsellem notes that his firm hasn't issued ...
Hosted on MSN25d
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds
Piper Sandler downgraded Biogen (NASDAQ ... Alzheimer's disease franchise (an uphill battle in our view)," Piper analyst David Amsellem wrote, adding, "We remain cautious on the AD franchise ...
Investing28d
Piper Sandler cuts Sage Therapeutics stock price target but sees recovery in PPD sales
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining an ...
Investing28d
Piper Sandler cuts Sage Therapeutics stock price target but sees recovery in PPD sales
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage (LON:SGE) Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining ...